Kenneth Ain is an Endocrinology/Metabolic physician affiliated with University of Kentucky. OpenAlex indexes 96 publications with 9,208 citations (h-index 43); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
740 S Limestone
Lexington, KY 405360001
Telephone
859-323-5821Registry record last updated 30 Apr 2012.
Clinical trials
- Thalidomide in Treating Patients With Thyroid Cancer
Sponsor: Kenneth Ain
- Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
Sponsor: Lucille P. Markey Cancer Center at University of Kentucky
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20241 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20231 payment
- GENZYME CORPORATIONProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
46%l-Thyroxine46%Levothyroxine Sodium97%Synthroid3%Part D<11 patientsCardiovascular
35.3%Beta blocker11.6%Metoprolol Succinate55%Labetalol Hcl22%Atenolol15%Metoprolol Tartrate9%Part D<11 patientsCalcium channel blocker8.7%Amlodipine Besylate100%Part D≥33 patients+ 4 more classes in this area
Cancer & immunology
11.8%Kinase inhibitor11.8%Sorafenib31%Mekinist19%Lenvima17%Tafinlar17%Retevmo16%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1994–2011 per NIH RePORTER. The latest:
- Transcriptional Repression of Sodium-Iodide Symporter in Thyroid Carcinoma
University of Kentucky
FY2011$226,495R01CA125166 - Transcriptional Repression of Sodium-Iodide Symporter in Thyroid Carcinoma
University of Kentucky
FY2010$151,000R01CA125166 - Transcriptional Repression of Sodium-Iodide Symporter in Thyroid Carcinoma
University of Kentucky
FY2009$126,000R01CA125166
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987–2012
The Journal of Clinical Endocrinology & Metabolism
2015 - The Impact of Age and Gender on Papillary Thyroid Cancer Survival
The Journal of Clinical Endocrinology & Metabolism
2012
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
Phillip Tibbs
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”